GLYC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 15:04):

Stats
Today's Volume	641 209
Average Volume	502 619
Market Cap	113.48M
EPS	$0 ( 2024-05-01 )
Next earnings date	( $-0.150 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.04
ATR14	$0.00500 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Koenig Scott	Buy	40 000	Stock Option (right to buy)
2024-05-01	Goldberg Mark Alan	Buy	40 000	Stock Option (right to buy)
2024-05-01	Pearson Timothy R	Buy	40 000	Stock Option (right to buy)
2024-05-01	King Rachel K.	Buy	40 000	Stock Option (right to buy)
2024-05-01	Andrews Patricia S	Buy	40 000	Stock Option (right to buy)

INSIDER POWER
29.87
Last 98 transactions
Buy: 6 982 849 \| Sell: 4 750 194

Volume Correlation

Long: -0.02 (neutral)

Short: -0.49 (neutral)

Signal:(57.019) Neutral

GlycoMimetics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlycoMimetics Inc Correlation - Currency/Commodity

-0.09
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

-0.65
( weak negative )

0.71
( moderate )

GlycoMimetics Inc Financials

Annual	2023
Revenue:	$10 000.00
Gross Profit:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2023
Revenue:	$10 000.00
Gross Profit:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2022
Revenue:	$74 925.00
Gross Profit:	$-957 231 (-1 277.59 %)
EPS:	$-1.780

FY	2021
Revenue:	$1 160.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.230

Financial Reports:

No articles found.

GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.